ELBA: Exemestane and Lapatinib in Advanced Breast Cancer
Status:
Withdrawn
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Aromatase inhibitors are the standard treatment for hormone responsive advanced breast
cancer. The combination of the aromatase inhibitor exemestane with with another breast cancer
drug that blocks epidermal growth factor receptor (EGFR) and Erb-2 activity (lapatinib) is
being studied for the possibility of improving response to therapy, and delaying resistance
to endocrine therapy.